Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Liabilities and Shareholders Equity: 2020-2023

Historic Liabilities and Shareholders Equity for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $102.6 million.

  • Immuneering's Liabilities and Shareholders Equity fell 39.80% to $68.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $336.2 million, marking a year-over-year decrease of 28.29%. This contributed to the annual value of $102.6 million for FY2023, which is 16.17% down from last year.
  • According to the latest figures from FY2023, Immuneering's Liabilities and Shareholders Equity is $102.6 million, which was down 16.17% from $122.4 million recorded in FY2022.
  • Over the past 5 years, Immuneering's Liabilities and Shareholders Equity peaked at $166.7 million during FY2021, and registered a low of $38.4 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $122.4 million (2022), whereas its average is $130.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 333.87% in 2021, then dropped by 26.60% in 2022.
  • Yearly analysis of 4 years shows Immuneering's Liabilities and Shareholders Equity stood at $38.4 million in 2020, then spiked by 333.87% to $166.7 million in 2021, then fell by 26.60% to $122.4 million in 2022, then decreased by 16.17% to $102.6 million in 2023.